Inflammatory bowel disease serologies in ankylosing spondylitis patients: a pilot study

被引:32
|
作者
Mundwiler, Matthew L. [2 ]
Mei, Ling [1 ]
Landers, Carol J. [1 ]
Reveille, John D. [3 ]
Targan, Stephan [1 ]
Weisman, Michael H. [1 ]
机构
[1] Cedars Sinai Med Ctr, Ctr Inflammatory Bowel Dis, Los Angeles, CA 90048 USA
[2] Rockford Orthoped Associates, Rockford, IL 61107 USA
[3] Univ Texas Hlth Sci Ctr, Houston, TX 77030 USA
关键词
CROHNS-DISEASE; SACCHAROMYCES-CEREVISIAE; MICROBIAL ANTIGENS; PSOAS COHORT; ANTIBODIES; ASSOCIATION; PREVALENCE; SPONDYLOARTHROPATHIES; AUTOANTIBODIES; ARTHRITIS;
D O I
10.1186/ar2866
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction Ankylosing spondylitis (AS) and inflammatory bowel disease (IBD) share similarities and are classified as spondyloarthropathies. In IBD, anti-Saccharomyces cerevisiae antibody (ASCA), anti-I2 (associated with anti-Pseudomonas activity), anti-Escherichia coli outer membrane porin C (anti-OmpC), anti-flagellin (anti-CBir1), and antineutrophil cytoplasmic antibodies (ANCA) possess clinical significance. Because of the overlap between the two conditions, a pilot study was designed to compare the frequency of these antibodies in AS patients compared to normal controls. Methods Serum stored from 80 AS patients and 80 control subjects was available for analysis. ASCA, anti-I2, anti-OmpC, anti-CBir1, and ANCA studies were completed on all serum samples using Enzyme-Linked Immunosorbent Assay (ELISA) methodology. The following analyses were performed: comparison of positivity based on the established values in IBD, median values, the number of subjects in each serology in the 4(th) quartile of a normal distribution, and the mean quartile sum of all the antibodies. Results There was no difference in positivity rates between AS and control groups with the established IBD values. The median anti-I2 response was significantly higher in AS than in controls (11.78 vs 7.86, p = 0.017). Significantly more AS patients had quartile scores of 4 for the following antibody responses: ASCA IgG (26% vs 13%, p = 0.016, OR = 2.49, CI 1.168-5.313), ASCA IgG and IgA (27% vs 12%, p = 0.006, OR = 2.9, CI: 1.342-6.264), and anti-I2 (25% vs 14%, p = 0.0424, OR = 2.15, CI: 1.018-4.538). The mean quartile sum of the antibody responses was elevated in AS patients when ANCA was excluded (10.526 vs 9.519, p = 0.03). When ANCA was included, this difference lost significance. Conclusions The data from this pilot study points towards mucosal dysregulation as an important pathway in AS. We were able to demonstrate that anti-I2 could play a pathologic role in AS. The elevated mean total antibody response being significant only with ANCA exclusion is consistent with the histopathological evidence that intestinal inflammation in AS is similar to Crohn's disease. To better define the roles of these antibodies in AS, larger studies with more precisely defined patient characteristics are required.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] Inflammatory Bowel Disease Is Associated with a Substantial Economic Burden in Patients with Psoriatic Arthritis and in Patients with Ankylosing Spondylitis
    Bergman, Martin J.
    Zueger, Patrick
    Song, Jinlin
    Pivneva, Irina
    Betts, Keith A.
    Joshi, Avani D.
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [32] IDENTIFICATION OF PATIENTS AFFECTED WITH ANKYLOSING SPONDYLITIS AND INFLAMMATORY BOWEL DISEASE OVERLAP USING COLLAGEN BIOMARKERS
    Nielsen, S. Holm
    Stahly, A.
    Regner, E. H.
    Bay-Jensen, A. C.
    Karsdal, M.
    Kuhn, K. A.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 748 - 748
  • [33] The effect of concomitant ankylosing spondylitis on long-term outcome of patients with inflammatory bowel disease
    Atay, Kadri
    Eyvazov, Hayyam
    Bozcan, Selma
    Eskazan, Tugce
    Demir, Nurhan
    Hatemi, Ibrahim
    Erzin, Yusuf
    Celik, Aykut Ferhat
    TURKISH JOURNAL OF GASTROENTEROLOGY, 2019, 30 (07): : 599 - 604
  • [34] Clinical, Serologic, and Genetic Associations Among Patients With Both Inflammatory Bowel Disease and Ankylosing Spondylitis
    Williams, Chadwick I.
    Karayev, Dmitry
    Learch, Thomas
    Targan, Stephan R.
    Landers, Carol J.
    Rotter, Jerome I.
    Vasiliauskas, Eric A.
    Ippoliti, Andrew
    Kaur, Manreet
    Melmed, Gil Y.
    Shih, David Q.
    Dubinsky, Marla
    Taylor, Kent D.
    Li, Dalin
    Weisman, Michael H.
    McGovern, Dermot P.
    GASTROENTEROLOGY, 2012, 142 (05) : S662 - S662
  • [35] EMERGENCE/EXACERBATION OF INFLAMMATORY BOWEL DISEASE IN PATIENTS RECEIVING SECUKINUMAB FOR ANKYLOSING SPONDYLITIS -CASE SERIES
    Tufail, Qamar
    Nakum, Shivanee
    Kadri, Sudarshan
    Hooper, Patricia
    Patel, Veena
    Harrison, Rebecca
    GUT, 2021, 70 : A127 - A128
  • [36] AGGRESSIVE INFLAMMATORY BOWEL DISEASE PHENOTYPE IN PATIENTS WITH ANKYLOSING SPONDYLITIS: A SINGLE-CENTER EXPERIENCE
    Rumman, Amir
    Al Malki, Fahd
    Al Ghamdi, Sarah
    Tabatabavakili, Sahar
    Cino, Maria
    Inman, Robert
    GASTROENTEROLOGY, 2018, 154 (06) : S624 - S624
  • [37] SPECTRUM OF ANKYLOSING-SPONDYLITIS IN PATIENTS WITH INFLAMMATORY BOWEL-DISEASE - CLINICAL AND GENETIC STUDIES
    DEKKERSAEYS, BJ
    MEUWISSEN, SGM
    VANDENBERGLOONEN, EM
    TYTGAT, GNJ
    GASTROENTEROLOGY, 1977, 72 (05) : 1047 - 1047
  • [38] Incidence rates of tuberculosis and inflammatory bowel disease in patients with ankylosing spondylitis treated with biologics in Korea
    Kwon, Oh Chan
    Lee, Hye Sun
    Yang, Juyeon
    Paul, Thomas
    Jin, Hyerim
    Lee, Youkyung
    Park, Min-Chan
    RHEUMATOLOGY, 2025,
  • [39] Quality of life in patients with ankylosing spondylitis:: a pilot study
    Turan, Yasemin
    Duruoez, Mehmet Tuncay
    Cerrahoglu, Lale
    RHEUMATOLOGY INTERNATIONAL, 2007, 27 (10) : 895 - 899
  • [40] Quality of life in patients with ankylosing spondylitis: a pilot study
    Yasemin Turan
    Mehmet Tuncay Duruöz
    Lale Cerrahoglu
    Rheumatology International, 2007, 27 : 895 - 899